



Prior Authorization Approval Criteria

Xeomin (incobotulinumtoxin A)

Generic name:	incobotulinumtoxin A
Brand name:	Xeomin
Medication class:	Neurotoxin
FDA-approved uses:	Cervical dystonia Blepharospasm previously treated with onabotulinumtoxin A
Available dosage forms:	50unit and 100unit single-use vials
Usual dose:	Cervical dystonia – 120 units per treatment Blepharospasm – 33 units per eye
Approximate treatment cost: (based on AWP 2011)	Cervical dystonia – \$945 Blepharospasm – \$315 per eye

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Prescribed by a dermatologist, neurologist, ophthalmologist, or physiatrist
- Must be greater than 18 years of age
- Must have at least one of the following conditions:
 - Cervical dystonia
 - Blepharospasm
 - Must have tried and failed treatment with Botox

Caution:

- Potency of units between different preparations of botulinum toxin products are not interchangeable
- Spread of toxin effects may cause swallowing and breathing difficulties

Contraindication:

- Pregnancy
- Sensitivity or allergic reaction to other botulinum toxins

Not approved if:

- Does not meet the above-stated criteria
- Has any contraindications to the use of dapsone
- Being used for the treatment of glabellar rhytids

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 09/07/2011